Physician profile
James Park
NPI 1114276854
$26,176.94
in general payments reported to CMS, 2019-2025
28 companies · $3,704 in 2025
The $3,704 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.98 · 2020: $7,025 · 2021: $3,623 · 2022: $3,927 · 2023: $2,655 · 2024: $5,228 · 2025: $3,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,838 · Food and Beverage: $2,445 · Travel and Lodging: $1,260 · Education: $44.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,837.50 |
| Food and Beverage | $2,444.61 |
| Travel and Lodging | $1,259.90 |
| Education | $44.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $21,041.22 | 2020-2025 | Xcopri |
| Ucb, INC. | $1,107.22 | 2020-2025 | Briviact, Nayzilam, Rystiggo |
| Sunovion Pharmaceuticals INC. | $832.71 | 2021-2022 | |
| Abbvie INC. | $519.24 | 2021-2025 | |
| Neurelis, INC. | $404.84 | 2020-2024 | Valtoco |
| Neuropace, INC. | $404.45 | 2022-2025 | |
| Eisai INC. | $317.67 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $272.24 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $256.47 | 2023 | Aptiom |
| Jazz Pharmaceuticals INC. | $191.72 | 2024-2025 | |
| Lilly USA, LLC | $145.53 | 2022-2023 | Amyvid |
| Aquestive Therapeutics, INC. | $106.92 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $91.28 | 2022 | |
| Banner Life Sciences, LLC | $61.45 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $55.37 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $53.50 | 2021 | |
| Allergan, INC. | $42.03 | 2020 | |
| Lundbeck LLC | $39.11 | 2022 | |
| Pfizer INC. | $37.15 | 2023-2024 | |
| Amgen INC. | $26.53 | 2022 | |
| Zogenix INC. | $25.16 | 2021 | |
| Csl Behring | $24.99 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $23.18 | 2020 | |
| Upsher-Smith Laboratories LLC | $22.54 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.44 | 2023 | Rexulti |
| Celgene Corporation | $20.76 | 2021 | |
| Impel Pharmaceuticals INC. | $16.43 | 2023 | Trudhesa |
| Almatica Pharma LLC | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.